Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2021 | $4.00 | Speculative Buy | Benchmark |
MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), has announced the appointment of Abby Macnish Niven as Alterity's Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024. The Board and Management of Alterity thank Phillip for his valuable contributions over the past several years and appreciate the foundation he helped establish. Ms Macnish Niven was appointed as CFO on 30 September 2024 and has extensive experience in private wealth man
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity's Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International Symposium on the Autonomic Nervous System. "The data presented highlights our work to better understand not only how multiple system atrophy (MSA) initially presents, but also how it progresses over time," said David Stamler, M.D., Chief Executive Officer of Alter
MELBOURNE, AUSTRALIA and SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the peer-reviewed journal, Metallomics has published data on the importance of iron and iron-targeting agents like ATH434 to treat neurodegenerative diseases. Metallomics publishes cutting-edge investigations that elucidate the dynamics, role, and impact of metals in biological systems. David Stamler, M.D., Chief Executive Officer of Alterity, commented, "Iron has long been implicated in neurodegeneration, bu
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), has announced the appointment of Abby Macnish Niven as Alterity's Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024. The Board and Management of Alterity thank Phillip for his valuable contributions over the past several years and appreciate the foundation he helped establish. Ms Macnish Niven was appointed as CFO on 30 September 2024 and has extensive experience in private wealth man
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company's Chief Financial Officer (CFO), effective today. "We look forward to Abby's contributions whose broad experience and financial background will help us advance our programs. I would also like to express my gratitude to Phillip and his team who supported us during a transition period," said David Stamler, M.D., Chief Executive Officer of Alterity. Ms Macnish Niven h
MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Phillip Hains as the Company's new Chief Financial Officer (CFO), effective 31 January 2024. Mr. Hains has served as the Company Secretary of Alterity since 2014, and his experience includes almost 30 years in corporate secretarial, accounting and general management through professional services firm Acclime and predecessor firm The CFO Solution. The appointment of Mr. Hains follows the resignatio
Benchmark initiated coverage of Alterity Therapeutics with a rating of Speculative Buy and set a new price target of $4.00
SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)
SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)
SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)